LoginSign Up
Betalin Therapeutics

Betalin Therapeutics

Biological micro-pancreas for insulin-dependent diabetics company

Betalin Therapeutics is developing an Engineered Micro Pancreas (EMP) to improve the quality of life for millions of people with diabetes.

Betalin Therapeutics licensed the novel EMP technology developed at The Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development.

Based on promising in vitro results and preliminary in vivo results, Betalin Therapeutics has recently submitted a pre-pre-IND (Investigational New Drug) application to the Food and Drug Administration (FDA). Following the FDA's positive response, Betalin Therapeutics is now preparing the pre-IND meeting on its way towards IND submission.

Betalin Therapeutics is currently raising funding in order to further optimize the therapy in animal models, complete submission of the IND application to the FDA, and proceed to clinical trials. Betalin Therapeutics was recently awarded a competitive matching grant from the Office of the Chief Scientist, doubling the value of investments made at this stage.

Timeline

Currently, no events have been added to this timeline yet.
Be the first one to add some.

People

Name
Role
Related Golden topics

Avi Treves

VP Research and Development

Eli Ishai

Advisory Board Member

Jacob Ben-Aire

CEO

Manuela Vecsler

Senior Scientist

Orit Goldman

Senior Scientist/ Lab manager

Shuki Joshua Hershcovich

Founder

Further reading

Author
Title
Link
Type

Betalin Therapeutics

Betalin Therapeutics Wins Startup Competition at MIXiii Biomed 2017

News article

Patricia Silva

Engineered Micro Pancreas Raises Hope for Type 1 Diabetes Treatment

Journal Article

Documentaries, videos and podcasts

Title
Date
Link

Betalin animation

Jan 25, 2016

Betalin information

Feb 26, 2018

Companies

Company
CEO
Location
Products/Services